ReviewJournal of mammary gland biology and neoplasia2005
VEGF-targeting therapy for breast cancer.
Review in Journal of mammary gland biology and neoplasia, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00991978 (Vascular Endothelial Growth Factor), which is not on this map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Vascular Endothelial Growth Factor (VEGF) Imaging for Early Breast Cancer Detection A Feasibility Study
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Gene expression meta-analysis identifies metastatic pathways and transcription factors in breast cancer.BMC cancer · 2008Pooled it
- Clinical Progress of Targeted Therapy for Breast Cancer: A Comprehensive Review.Current cancer drug targets · 2025Review
- Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma.Journal of translational medicine · 2023Article
- Chemopreventive Properties of Black Raspberries and Strawberries in Esophageal Cancer Review.Antioxidants (Basel, Switzerland) · 2022Review
- DNA-Liposome Hybrid Carriers for Triggered Cargo Release.ACS applied bio materials · 2022Article
- Down-regulation of CITED2 attenuates breast tumor growth, vessel formation and TGF-β-induced expression of VEGFA.Oncotarget · 2017Article
- Clinical implications of DLL4 expression in gastric cancer.Journal of experimental & clinical cancer research : CR · 2013Article
- Biomarkers for Basal-like Breast Cancer.Cancers · 2010Article
- Evaluation of the current knowledge limitations in breast cancer research: a gap analysis.Breast cancer research : BCR · 2008Review
- Precursors and preinvasive lesions of the breast: the role of molecular prognostic markers in the diagnostic and therapeutic dilemma.World journal of surgical oncology · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vascular Endothelial Growth Factor (VEGF) plays an important role in multiple physiologic and pathologic processes involving endothelial cells. Several preclinical and clinical sources of evidence suggest its importance in human breast cancer. Based on the presumed biologic relevance of VEGF in human breast cancer, clinical trials using agents targeting VEGF were launched beginning in the late 1990s. This clinical trial effort came to fruition in 2005 with the success of the first large, prospective randomized trial of anti-VEGF therapy in patients with front-line metastatic breast cancer, which demonstrated the benefit of adding the monoclonal anti-ligand antibody bevacizumab to the chemotherapeutic agent paclitaxel. Based upon this success, numerous anti-VEGF agents are now being tested in patients with breast cancer, and adjuvant therapy trials are in development. Nevertheless, important questions remain regarding the biology and clinical development of these agents in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.